Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT07477587
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Phase 1 · Australia, China, Georgia, Serbia, United States · 84 sites
Registry update: 24 Sept 2026
2025-524022-18-00
Recruiting
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
Phase 2 · Sweden · 14 sites
Registry update: 16 Feb 2026
NCT07638683
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Phase 2 · China · 1 site
Registry update: 3 Aug 2026
NCT07479979
Recruiting
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 · United States · 1 site
Registry update: 31 Aug 2026
NCT07393282
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · Germany, Spain, France, United Kingdom, Greece, Italy, Japan, South Korea, Norway, Poland, United States · 75 sites
Registry update: 4 Nov 2026
NCT05976555
Recruiting
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Phase 1 · United States · 1 site
Registry update: 10 Aug 2026
NCT07609576
Recruiting
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Not applicable · Spain · 2 sites
Registry update: 27 May 2026
NCT07582432
Recruiting
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Phase 3 · Czechia, Spain, France, Italy, Poland, United States · 27 sites
Registry update: 1 Oct 2026
NCT07541391
Recruiting
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Phase 1 · Australia · 1 site
Registry update: 27 May 2026
NCT07053436
Recruiting
Horizon Two: HR NDMM (MMRC-100)
Phase 2 · United States · 12 sites
Registry update: 2 Oct 2026
NCT07609030
Recruiting
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
Not applicable · United States · 1 site
Registry update: 27 May 2026
NCT07426484
Recruiting
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Phase 4 · United States · 2 sites
Registry update: 11 Aug 2026
NCT07485647
Recruiting
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Phase 2 · United States · 1 site
Registry update: 19 Aug 2026
NCT07249528
Recruiting
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Not applicable · United States · 8 sites
Registry update: 13 Oct 2026
NCT07454187
Recruiting
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 · China · 4 sites
Registry update: 10 Jul 2026
NCT07227311
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Phase 2 · Germany, Spain, France, Greece, Japan, South Korea, Netherlands, United States · 56 sites
Registry update: 25 Aug 2026
NCT07493135
Recruiting
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Early phase 1 · China · 4 sites
Registry update: 3 Sept 2026
NCT07292272
Recruiting
Halt Aging in Survivors of Blood Cancers
Not applicable · United States · 1 site
Registry update: 1 Jul 2026
NCT07446777
Recruiting
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Not applicable · United States · 1 site
Registry update: 1 May 2026
NCT07440290
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Phase 2/3 · United Kingdom · 27 sites
Registry update: 17 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.